The Middle East and Asia injectable drugs market comprises drugs that are administered into the body via various routes such as intravenous, intramuscular, and subcutaneous. Prefilled syringes are gaining traction in the region owing to their advantages like accurate dosing, less wastage of drugs, and easy administration. The increasing prevalence of chronic diseases like cancer and diabetes is propelling the demand for injectable drugs in Asia and the Middle East. Therapeutic areas where injectable drugs are widely used include oncology, autoimmune diseases, and infectious diseases.
The global Middle East And Asia injectable drugs market is estimated to be valued at US$ 4,15,000 Million in 2021 and is expected to exhibit a CAGR of 8.2% over the forecast period 2021-2028.
Key Takeaways
Key players operating in the Middle East And Asia Injectable Drugs are Pfizer, Sanofi, Novartis, F. Hoffmann-La Roche and GlaxoSmithKline. The rising demand for biosimilars and generic injectable drugs presents significant opportunities in Asia and the Middle East injectable drugs market . Advancement in prefilled syringe technology is facilitating self-administration of drugs. This is expected to further drive the market growth over the forecast period.
Middle East And Asia Injectable Drugs Market Growth include biologics and biosimilars. The significant rise in chronic diseases, rapid economic development, and increasing healthcare expenditures are fueling the demand for advanced biologic drugs in the region. Technological advancements are also enabling easier administration of drugs through prefilled syringes and auto-injectors.
Market drivers:
The growing geriatric population is a major driver of the Middle East and Asia injectable drugs market. The number of older adults in Asia and the Middle East is increasing rapidly. With age comes the increased likelihood of developing chronic diseases like diabetes that require frequent injection of drugs. Another key factor is the rising demand for self-administered injectable drugs owing to the increasing cases of chronic diseases. Prefilled syringes have made drug self-administration safer and more convenient. This has positively impacted the growth of the injectable drugs market in Asia and the Middle East.
Current Challenges in Middle East And Asia Injectable Drugs Market
The Middle East and Asia injectable drugs market is facing several challenges currently which are hindering its growth potential. One of the major challenges is lack of proper healthcare infrastructure and facilities in many developing nations. This restricts appropriate adoption of new and advanced injectable drugs. Secondly, high costs associated with R&D and production of specialized injectable drugs is a barrier, especially for small manufacturers. Ensuring drug safety and quality standards as per regulatory norms of different countries is another regulatory challenge. Healthcare access and affordability issues in rural and remote areas is another critical problem due to low per capita income levels in some parts. Managing complex supply chains and cold chain infrastructure for temperature-sensitive injectable drugs poses logistical challenges as well. Overall, efforts are required to strengthen healthcare infrastructure and ensure access to affordable treatment options to unlock the full market potential.
SWOT Analysis
Strength: Growing aging population and disease prevalence in the region is driving strong demand for injectable drugs. Weakness: High dependency on imports make the market vulnerable to supply disruptions. Opportunity: Emerging biosimilars market and investments in healthcare infrastructure offers new opportunities. Threats: Price control regulations and intellectual property related issues pose threats.
Geographical regions in the Middle East And Asia Injectable Drugs Market where value is concentrated:
The Middle East region currently accounts for the largest share in terms of value in the Middle East and Asia injectable drugs market. Countries like Saudi Arabia, United Arab Emirates, Iran hold majority of the market share due to higher healthcare spending capabilities and demand for specialty injectable drugs. India also generates sizable revenues supported by its huge population base and growth in non-communicable diseases.
Fastest growing region in the Middle East And Asia Injectable Drugs Market:
China is anticipated to be the fastest growing geographical region during the forecast period in the Middle East and Asia injectable drugs market. This can be attributed to factors like rising income levels, increasing health awareness, expanding health insurance coverage and heavy government focus on strengthening the healthcare system. Recent regulatory reforms have also boosted pharmaceutical industry growth in China.
Get This Report in Japanese Language: 中東・アジアの注射剤市場
Get This Report in Korean Language: 중동 및 아시아 주사제 시장
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
0 comment